Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics...
Transcript of Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics...
![Page 1: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/1.jpg)
Application of Physiologically Based Biopharmaceutics Modeling in Support
of Drug Product Quality
Yang Zhao, PhD Division of Biopharmaceutics/ONDP/OPQ/CDER/FDA
2019 FDA-PQRI Conference
![Page 2: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/2.jpg)
2
Disclaimer
This presentation reflects the views of the presenter and should not be construed to
represent the FDA's views or policies.
![Page 3: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/3.jpg)
3
Outline • Overview of review tasks at Division of
Biopharmaceutics in FDA• Physiologically-Based Biopharmaceutics Modeling
(PBBM) in support of drug product quality– Common applications– Common deficiencies– Model workflow - general strategy– Case study
• Summary/Take Home Message
![Page 4: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/4.jpg)
4
Overview of review tasks at FDA’s Division of Biopharmaceutics
Biopharmaceutics
Dissolution/In vitro Release
ER claim
IVIVCIVIVR
Mechanistic modeling
QbDRisk
AssessmentDesign space verification
Biowaivers (BCS, CFR, Safe Space
based)
RTRT dissolution
models
Patient-centric product quality
Clinically relevant specifications
![Page 5: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/5.jpg)
5
Common regulatory applications of PBBM in support of drug product quality
Dissolution method, Acceptance criteria
(AC)
•Bio-predictive ability of dissolution method
•Clinically relevant dissolution AC/wider
AC
Clinically relevant specifications of CMAs and CPPs
CMAs (e.g., particle size, polymorphic form)
CPPs (e.g., milling, compression
force/hardness process evaluation)
Quality related Bio-waiver
•Waiver request based on physiologically based IVIVC/IVIVR
Formulation impacts
Formulation-related food effect
API form change or formulation change on
PPI interactions
Prediction of product performance by looking
at GI local drug concentration and
regional absorption
![Page 6: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/6.jpg)
6
Number of NDA submissions containing PBBM in support of drug product quality (2008-2018)
Mod
elin
g ap
plic
atio
n
![Page 7: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/7.jpg)
7
Number of ANDA submissions containing PBBM in support of drug product quality (since 2016)
Modeling application seen so far
![Page 8: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/8.jpg)
8
Common PBBM deficiencies observed in FDA submissions
• Model is not mechanistically sound, – Lack of parameter plausibility– API driven or formulation driven dissolution/absorption misinterpreted– In vitro dissolution not bio-predictive or not reflecting the in vivo dissolution– Assumption of 100% bioavailability, while incomplete absorption was indicated by in vivo study
• Verification data is insufficient, – Not objective oriented model verification – Inappropriate data selection for model verification– Additional verification needed for the intended purpose
• Model structure information is insufficient, – No formulation information– No mechanistic framework accounting for impact of quality attributes on absorption– No justification for input parameter values selected in drug, PK, formulation, physiology– Insufficient data/program files
• Reliability of simulation results is questionable, – Uncertainty of subject variability
![Page 9: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/9.jpg)
How to develop PBBM?
![Page 10: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/10.jpg)
10
Model Development
Model verification
Mod
el re
finem
ent
“Lea
rn a
nd C
onfir
m”
Model application
Model Objective(s)
Structure AssumptionsParameters
Acceptable? No
Yes
Physiologically-Based
Biopharmaceutics Modeling workflow
![Page 11: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/11.jpg)
11
Case study:• Objective: To establish clinically relevant API particle
size specification/formulation design space for a BCS class IV immediate release oral dosage formulation
• Oncology drug for treatment of leukemia• Immediate release capsule• 2 strengths: low and high compositionally proportional• BCS class 4 • High strength used in model development• Wide particle size range used in pivotal clinical trials
![Page 12: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/12.jpg)
12
Drug parameters:MW 417
pKa 3.9
logP 2.6
Solubility
PeffDensity
0.14 x 10-4 cm/sec (human) 1.37 g/mL
Dissolution Rapid dissolution in acidic medium
![Page 13: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/13.jpg)
13
Modeling workflow
Parameter sensitivity analysis (PSA)
Base model development using IV and PO data
Model modification/refinement using clinical data at 6 different
doses
Model verification/validation using 5 sets of independent
clinical dataRegulatory decision
Virtual bioequivalence (BE) to define clinically relevant PSD
limits
Model application
“Lea
rn an
d Con
firm”
![Page 14: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/14.jpg)
14
Modeling input and outputAPI and product formulation input:
Solubility vs. pH profileslogP, pKa
Dose and dose volumeDiffusion coefficient
PermeabilityMetabolic/transport kinetics
Dissolution: IR: particle size and density; MR: dissolution
profiles
Model output:PK profiles
CmaxAUC
TmaxIn vivo dissolution
Fa, FgF
Drug in regional GI
Physiology input: pH in GI
GI transit timeGI fluid volume
Bile saltEnzymes/transporters distribution
Blood flow
PK input:Clearance
VdInter-compartment rate constant
Protein bindingTissue/organ parameters for drug distribution
and elimination
Input determines your output!
![Page 15: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/15.jpg)
15
PSA showing the effect of particle size on systemic exposure
Conduct PSA for your parameters of uncertainty!
![Page 16: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/16.jpg)
16
Virtual BE supporting regulatory decision
Setting clinically relevant particle size
virtual BE based on a cross-over study design between(T): upper bounds of particle size within the specification vs.(R): lower bounds
Conduct virtual BE to take into consideration variability of individual parameters !
![Page 17: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/17.jpg)
17
SummaryThe use of Physiologically-Based Biopharmaceutics Modeling contributes to:
– Enhanced drug product understanding, in conjunction with quality by design (QbD) approach
– Patient-centric product quality– Establishment of in vitro and in vivo link, a key element in setting
clinically relevant drug product specifications– Potential reduction in the number of in vivo BA/BE studies (e.g.,
due to formulation or manufacturing process changes) prior to approval process or post-approval changes.
![Page 18: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/18.jpg)
18
Take home messages (1): A few questions to raise before developing a model
• What is the proposed model purpose or intended regulatory use?
• Are there sufficient data for model development and verification to justify the intended purpose?
• Are the data robust?• What is the appropriate model strategy?• Early communication with Division of Biopharmaceutics is
encouraged!
![Page 19: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/19.jpg)
19
Take home messages (2): Document checklist for FDA submission (not limited to)
• Model report (stating model objective and your “thought” process)• Modeling workflow• Drug product/formulation information and process understanding• Solubility data • Relevant dissolution information and dissolution profile data• PK data and study design• Sources of parameters• Coding or mathematical equations• Hypothesis • Datasets (allowing executing independent analysis)
![Page 20: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/20.jpg)
20
Acknowledgements
• Division of Biopharmaceutics– Dr. Paul Seo– Dr. Sandra Suarez– Dr. Angelica Dorantes– Dr. Kimberly Raines– Dr. Min Li– Dr. Ho-pi Lin
• ORS/DQMM– Dr. Fang Wu
![Page 21: Application of Physiologically Based Biopharmaceutics ...• Physiologically-Based Biopharmaceutics Modeling (PBBM) in support of drug product quality – Common applications – Common](https://reader030.fdocuments.in/reader030/viewer/2022040213/5e938325bb311f0d9b154b29/html5/thumbnails/21.jpg)
Thank you!